同种异基因小鼠骨髓移植后NK-T细胞激活剂α-GalCer加速免疫和造血重建  

NK-T Cell Activator (α-GalCer) Accelerates Immune and Hematogical Reconstitution after Murine Allo-Bone Marrow Transplantation

作　　者：刘景华[1] 周凡[1] 窦立萍[2] 刘彦琴[1] 王吉刚[1] 白颖[1] 郭步云[1] 于力[2] 

机构地区：[1]沈阳军区总医院血液科,辽宁沈阳110016 [2]解放军总医院血液科,北京100853

出　　处：《中国实验血液学杂志》2010年第6期1542-1547,共6页Journal of Experimental Hematology

基　　金：国家自然科学基金面上项目;编号30670898

摘　　要：造血干细胞移植后的并发症如感染、GVHD及疾病复发等均与免疫重建密切相关。本研究探讨一种特异的NK-T细胞激活剂α-galactosyleramide(α-GalCer)是否有加速移植后免疫和造血重建的作用。供鼠为C57BL/6小鼠,受鼠为BALB/c小鼠。实验组在骨髓移植后立即腹腔注射α-GalCer,对照组在骨髓移植后立即腹腔注射DMSO。移植后观察小鼠体重、体位、活动性、毛发、腹泻及生存期;于第2、7、14、27、70天检测供者细胞嵌合体、脾单个核细胞数及CD3+、CD4+、CD8+、B220+、CD11c+、CD40+、CD86+、CD80+细胞的相对计数,并每周检测外周血白细胞及血红蛋白。结果表明:在移植后早期第2天,用药组脾脏单个核细胞计数及CD3+细胞、CD4+细胞比例均较对照组高,此时检测供者细胞嵌合体两组均完全为受者型,之后逐渐转变为供者型,在移植后第7-14天用药组供者细胞嵌合体较对照组明显增高。在移植后第27天,两组均完全为供者型,此后至第70天用药组脾脏单个核细胞计数及CD3+、CD4+、CD8+、B220+、CD40+、CD86+细胞比例均明显高于对照组,同时用药组造血重建较对照组加速。结论:同种异基因小鼠骨髓移植后α-GalCer的应用加速免疫和造血重建。Immune reconstitution is crucially relevant for patients receiving hematopoietic stem cell transplantation （HSCT）. This study was purposed to investigate the ability of α-GalCer （α-galactosyleramide）, a well-known activator of natural killer T cells （NK-T）, to enhance immune and hemological reconstitution. Lethally irradiated BALB/c mice were transplanted with allogeneic C57BL/6 bone marrow cells and splenocytes. α-GalCer was administered immediately after HSCT. After transplantation, the weight, activity, hairs, diarrhea and survival time of mice were observed daily; the blood routine test was performed once weekly; the donor chimeras, amount of mononuclear cells in spleen （MNC） and relative levels of CD3＋, CD4＋, CD8＋, B220＋, CD11c＋, CD40＋, CD86＋ and CD80＋ cells were detected by FACS on day 2, 7, 14, 27, 70 after transplantation. The results indicated that the MNC counts and relative levels of CD3＋ and CD4＋ in group treated with α-GalCer on day 2 after transplantation were higher than those in control group; at the same time, the detected donor chimeras were complete recipient type chimeras, then gradually transformed into donor type, on day 7-14 donor chimeras in α-GalCer group were enhanced significantly as compared with control group, on day 27 the chimeras in two groups were complete donor type chimeras thereafter to day 70, the MNC count and relative levels of CD3＋, CD4＋, CD8＋, B220＋, CD40＋, CD86＋ cells in α-GalCer group were obviously higher than those in control group, at the same time, the hematopoietic reconstitntion in α-GalCer group was accelerated as compared with control group. It is concluded that the α-GalCer administration after allogeneic bone marrow transplantations accelerates immune and hematogical reconstitution.

关 键 词：免疫重建 造血重建 骨髓移植 NK-T细胞激活剂 Α-GALCER 

分 类 号：R457.7[医药卫生—治疗学] R392.4[医药卫生—临床医学]